Antibody-Dependent Cellular Phagocytosis (ADCP) is a key immune mechanism in which antibodies coat target cells, such as tumor or infected cells, promoting their engulfment and clearance by phagocytic cells, including macrophages. ADCP plays a crucial role in maintaining immune surveillance and significantly contributes to the therapeutic efficacy of many monoclonal antibodies. It complements other antibody-mediated functions, such as ADCC, offering a broader immune response. In drug development, ADCP assays are essential for evaluating the functional potency of antibody candidates.
BIOENSIS' ADCP assays enable the comprehensive evaluation of therapeutic antibody efficacy using advanced culture systems. As part of our cutting-edge immuno-oncology platform, this immune cell-based assay utilizes human monocyte-derived macrophages to deliver robust and predictive data on antibody function. Our platform generates meaningful insights into ADCP mechanisms, enabling more predictive preclinical data.
Key assay features:
• Access to over 150 well-characterized tumor cell lines
• Functional human monocytes-derived macrophages
• High-throughput screening format for efficient and scalable testing
• Precision EC₅₀ determination for accurate potency assessment
• Flexible protocols accommodating both single agents and combination therapies
• Available in 2D and 3D cultures formats
Please contact us to discuss your study and an up to date list of available cell lines
info@bioensis.com
